雙成藥業(002693.SZ)擬3920萬元取得注射用紫杉醇(白蛋白結合型)項目技術
格隆匯6月8日丨雙成藥業(002693.SZ)公佈,公司(“甲方”)擬與公司關聯方寧波守正藥物研究有限公司(“寧波守正”、“乙方”)簽訂《技術轉讓合同》,寧波守正將其擁有注射用紫杉醇(白蛋白結合型)項目的技術祕密全部轉讓給公司,公司受讓並支付相應的轉讓費人民幣3920.00萬元。
寧波守正的股東為海南至德成大科技發展有限公司(“至德成大”)及張立萍。至德成大的股東為王成棟及張立萍。張立萍為公司實際控制人王成棟之配偶、Wang Yingpu之母親。根據《深圳證券交易所股票上市規則》的相關規定,該交易事項構成關聯交易。
注射用紫杉醇(白蛋白結合型)是一種由白蛋白包裹紫杉醇形成的納米微粒製劑,原研藥商品名:凱素(Abraxane)。經白蛋白包裹製成納米微粒後,比其它紫杉醇藥品相比注射用紫杉醇(白蛋白結合型)細胞毒性副作用顯著降低,劑量增大,抗腫瘤作用增強。此外,注射用紫杉醇(白蛋白結合型)可在腫瘤中產生積蓄,定向釋放至腫瘤細胞,具有靶向性,進一步提高藥物的療效。
公司取得注射用紫杉醇(白蛋白結合型)項目技術,有利於豐富公司產品結構,增強公司綜合競爭實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.